Is Romiplostim on the market?

Romiplostim was developed by Amgen through a restricted use program called NEXUS, and during development and clinical trials the drug was known as AMG531. Designated as an orphan drug by the U.S. Food and Drug Administration (FDA) in 2003, the FDA approved romiplostim in August 2008 as a long-term treatment for chronic ITP in adults who have not responded to other treatments such as corticosteroids, intravenous immunoglobulin, Rho(D) immunoglobulin, or splenectomy.

Romigrastim is a potential treatment for chronic idiopathic (immune) thrombocytopenic purpura (ITP). It is also used to treat acute radiation syndrome. To reduce bleeding caused by radiation, romigrastim stimulates the body to produce platelets. The drug is available to treat adults and children. Treatment is usually given weekly by subcutaneous injection. Before injection, perform a complete blood count (CBC) as dosage depends on the patient's weight and platelet count at the time of treatment.

RomiplostimThe original drug has been approved by the State Food and Drug Administration for marketing. Due to its short time on the market, it is not included in the scope of medical insurance. It may be difficult to purchase it domestically. The price of the original version in Hong Kong may be RMB 10,000 per pill (the price may fluctuate due to exchange rates). The price of the European version of romiplostim the original drug may be 11,000 RMB per pill, the German version may be 9,850 RMB per pill, and the Hong Kong version may be 8,900 RMB per pill (the price may fluctuate due to the exchange rate). The ingredients of the drugs are basically the same. For specific prices and drug details, please consult Yaode’s medical consultant.